Clinical response to transurethral microwave thermotherapy is thermal dose dependent

Eur Urol. 1993;23(2):267-74. doi: 10.1159/000474611.

Abstract

Transurethral microwave thermotherapy of the prostate was used to treat men with symptomatic benign prostatic hypertrophy. Three treatment protocols delivering increasing thermal doses (Prostasoft T-A > Prostasoft II > Prostasoft I) were evaluated. The results show a dose-dependent response. Histological changes induced by microwave heating were dependent on the temperature achieved in the tissue. Thermocoagulation is obtained above 45 degrees C and thermoablation above 60 degrees C. Using Prostasoft II in a long-term follow-up study, the Madsen symptom score decreased by 66% and peak flow rates increased by 41% over a period of more than 18 months. Using Prostasoft T-A (thermoablation) in 28 patients, a cavity was obtained inside the prostate without major complication. The symptoms and obstruction caused by benign prostatic hypertrophy can be treated by transurethral thermotherapy in a single, anesthesia-free 1-hour session on an ambulatory basis.

MeSH terms

  • Follow-Up Studies
  • Humans
  • Hyperthermia, Induced*
  • Male
  • Microwaves*
  • Prostate-Specific Antigen / metabolism
  • Prostatic Hyperplasia / metabolism
  • Prostatic Hyperplasia / pathology
  • Prostatic Hyperplasia / therapy*
  • Software
  • Urethra

Substances

  • Prostate-Specific Antigen